FDA rolls out new conflict rules

The Food and Drug Administration linkurl:unveiled;http://www.fda.gov/bbs/topics/NEWS/2008/NEW01871.html new, tougher linkurl:conflict of interest;http://www.the-scientist.com/news/display/24056/ rules yesterday (Aug 4). Key among the regulations was one that linkurl:prohibits;http://www.fda.gov/oc/advisory/GuidancePolicyRegs/ACWaiverCriteriaFINALGuidance080408.pdf physicians or researchers who have more than $50,000 worth of financial interests in pharmaceutical or medical device companies from

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The Food and Drug Administration linkurl:unveiled;http://www.fda.gov/bbs/topics/NEWS/2008/NEW01871.html new, tougher linkurl:conflict of interest;http://www.the-scientist.com/news/display/24056/ rules yesterday (Aug 4). Key among the regulations was one that linkurl:prohibits;http://www.fda.gov/oc/advisory/GuidancePolicyRegs/ACWaiverCriteriaFINALGuidance080408.pdf physicians or researchers who have more than $50,000 worth of financial interests in pharmaceutical or medical device companies from offering expert advice as members of linkurl:FDA advisory panels.;http://www.the-scientist.com/blog/display/53953/ The new rules, issued in one draft guidance and four final guidance documents, also state that the FDA will linkurl:publically release;http://www.fda.gov/oc/advisory/GuidancePolicyRegs/AC48HourFINALGuidance080408.pdf briefing materials pertaining to advisory committee meetings no later than 48 hours before the meeting occurs, and that votes taken at these meetings will occur linkurl:simultaneously;http://www.fda.gov/oc/advisory/GuidancePolicyRegs/ACVotingFINALGuidance080408.pdf rather than sequentially, avoiding the potential for one vote to affect the next. The FDA also claims to have made its linkurl:Web site;http://www.fda.gov/ more navigable so that the public can easily access information relating to advisory panels. "It's imperative that we seek advice from independent experts, and that we do so in a way that is public, open, and transparent," said Randall Lutter, FDA's deputy commissioner for policy, in a linkurl:statement;http://www.fda.gov/bbs/topics/NEWS/2008/NEW01871.html from the agency. "Today's announcement strengthens our processes." The guidances were issued in response to a linkurl:law;http://www.fda.gov/oc/initiatives/HR3580.pdf that, in part, required the FDA to progressively cut back on the number of conflict of interest waivers it issues to advisory panel members who report financial interests but posses "essential expertise." The current rules do allow for such waivers to be granted for potential panel members who report less than $50,000 in pertinent financial interests. linkurl:Merrill Goozner,;http://www.the-scientist.com/blog/display/54836/ director of the Integrity in Science Project at the research watchdog group Center for Science in the Public Interest, said that the new rules are a step in the right direction. "[The FDA is] eliminating people with gross conflicts of interest," he said. "That's a start." But Goozner said that while the new FDA conflict rules are welcomed, the agency can do more to address conflicts of interest and other issues surrounding drugs and health care such as post-market monitoring and comparative effectiveness research. "[The new conflict rules] establish some interesting precedents and we look forward to continuing to push [the FDA] to further toughen the rules," he said. "There's just a whole host of issues that get wrapped up into making our health care system more effective and efficient."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio